<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Accumulating evidence suggests that combination therapy using oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents with different mechanisms of action may be highly effective in achieving and maintaining target blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of our study is to evaluate the differential effect on <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> parameters of the association between <z:chebi fb="0" ids="5383">glimepiride</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> in patients affected by type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients were enroled, evaluated and followed at two Italian centres </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated 99 type 2 diabetic patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (48 males and 47 females; 23 males and 24 females, aged 52 +/- 5 with <z:chebi fb="0" ids="5383">glimepiride</z:chebi>; 25 males and 23 females, aged 54 +/- 4 with cglitazone) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> were required to have been diagnosed as being diabetic for at least 6 months and did not have glycaemic control with diet and oral hypoglycaemic agents such as sulphonylureas or <z:chebi fb="0" ids="6801">metformin</z:chebi>, both to the maximum tolerated dose </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients took a fixed dose of <z:chebi fb="0" ids="6801">metformin</z:chebi>, 1500 mg/day </plain></SENT>
<SENT sid="6" pm="."><plain>We administered <z:chebi fb="0" ids="5383">glimepiride</z:chebi> (2 mg/day) or <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (4 mg/day) in a randomized, controlled, double-blind clinical study </plain></SENT>
<SENT sid="7" pm="."><plain>We evaluated body mass index (BMI), glycaemic control, <z:chebi fb="23" ids="18059">lipid</z:chebi> profile [total cholesterol (TC), <z:chebi fb="1" ids="47774">low-density lipoprotein-cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>), <z:chebi fb="1" ids="47775">high-density lipoprotein-cholesterol</z:chebi> and <z:chebi fb="4" ids="17855">triglycerides</z:chebi>] and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> parameters [<z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A-I and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (Apo B)] during 12 months of this treatment </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: A total of 95 patients completed the study </plain></SENT>
<SENT sid="9" pm="."><plain>Significant BMI decrease was observed at 12 months in <z:chebi fb="0" ids="5383">glimepiride</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group (p &lt; 0.05 and p &lt; 0.01 respectively) as well as of glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> decrease (p &lt; 0.05 and p &lt; 0.01 respectively), mean fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and postprandial plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (p &lt; 0.05 and p &lt; 0.01 respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>A decrease in fasting plasma insulin and postprandial plasma insulin at 12 months (p &lt; 0.05 and p &lt; 0.01 respectively) compared with the baseline value in <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group was observed </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, homeostasis model assessment index improvement was obtained only at 9 and 12 months (p &lt; 0.05 and p &lt; 0.01 respectively) compared with the baseline value in <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group </plain></SENT>
<SENT sid="12" pm="."><plain>Significant TC, <z:chebi fb="0" ids="47774">LDL-C</z:chebi> and Apo B improvement (p &lt; 0.05 respectively) was present in <z:chebi fb="0" ids="5383">glimepiride</z:chebi> group after 12 months compared with the baseline values, and these variations were significant (p &lt; 0.05) between groups </plain></SENT>
<SENT sid="13" pm="."><plain>Of the 95 patients who completed the study, 8.5% of patients in <z:chebi fb="0" ids="5383">glimepiride</z:chebi> group and 12.5% of patients in <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group had side-effects (p = not significant) </plain></SENT>
<SENT sid="14" pm="."><plain>Four patients had transient side-effects in <z:chebi fb="0" ids="5383">glimepiride</z:chebi> group and six patients in <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group </plain></SENT>
<SENT sid="15" pm="."><plain>Altogether, we did not have statistically significant changes in transaminases </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: The <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>-<z:chebi fb="0" ids="6801">metformin</z:chebi> association significantly improve the long-term control of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0000855'>insulin-resistance</z:hpo>-related parameters in comparison with the <z:chebi fb="0" ids="5383">glimepiride</z:chebi>-<z:chebi fb="0" ids="6801">metformin</z:chebi>-treated group </plain></SENT>
<SENT sid="17" pm="."><plain>On the other side, <z:chebi fb="0" ids="5383">glimepiride</z:chebi> treatment is associated to a slight improvement in cholesterolaemia, not observed in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>-treated patients </plain></SENT>
</text></document>